Nall says Prognos uses data that Biocept generates with its liquid biopsy tests from different cancers to analyze trends to identify and develop targeted therapies based on the genomic of a patient's tumor. Nall says investors should look out for how Biocept and Prognos sell this data to Big Pharma and create an additional revenue stream.
Investor deep dive
Biocept changing the way physicians examine blood work for their cancer patients
Biocept brings tremendous value to the healthcare system with its AI partnership
Quick facts: Biocept Inc
Market Cap: $22.1 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE